Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov66710.25208/vdv667ArticlesСтатьиResearch ArticleFirst clinical experience of the use of ustekinumab (Stelara) for treatment of psoriatic patients in RussiaПЕРВЫЙ КЛИНИЧЕСКИИ ОПЫТ ПРИМЕНЕНИЯ ПРЕПАРАТА УСТЕКИНУМАБ (СТЕЛАРА) В ТЕРАПИИ БОЛЬНЫХ ПСОРИАЗОМ В РОССИИZnamenskayaL FЗнаменскаяЛ Ф

к.м.н., заведующий отделом дерматологии

znaml@cnikvi.ruSvishchenkoS IСвищенкоС И

врач-дерматовенеролог отделения клинической дерматологии

ФГБУ «ГНЦДК» Минздравсоцразвития Россиии15042012882NO2 (2012)№2 (2012)485211032020Copyright ©; 2012, Znamenskaya L.F., Svishchenko S.I.Copyright ©; 2012, Знаменская Л.Ф., Свищенко С.И.2012Znamenskaya L.F., Svishchenko S.I.Знаменская Л.Ф., Свищенко С.И.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/667

The authors examined the efficacy and safety of treatment of patients suffering from moderate to severe forms of psoriasis with ustekinumab (blocker of р40 subunit of interleukin-12 and interleukin-23) taking into account the PASi index. They revealed high clinical efficacy of ustekinumab for treatment of psoriatic patients.

Изучена эффективность и безопасность лечения больных со среднетяжелыми и тяжелыми формами псориаза препаратом устекинумаб (блокатором субъединицы р40 интерлейкинов-12 и -23) с учетом значений индекса PASI. Установлена высокая клиническая эффективность устекинумаба в терапии больных псориазом.

monoclonal antibodiespsoriasisustekinumab (Stelara)biological drugsмоноклональные антителапсориазустекинумаб (Стелара)биологические препаратыPhung O.J., White C.M., Craig I. Coleman Ustekinumab: A human monoclonal antibody for the treatment of plaque psoriasis. Formulary 2009 (Mar 1).Christophers E. Psoriasis — Epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314—320.Инструкция по медицинскому применению препарата Стелара. Рег. номер, ЛСР-006465/09.Gottlieb A., Korman N.J., Gordon K.B. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008 (May); 58 (5): 851—864.Gottlieb A., Menter A., Mendelsohn A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373 (9664): 633—640.Krueger G.G., Langley R.G., Leonardi C., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356 (6): 580—592.O'Neill J.L., Kalb R.E. Ustekinumab in the therapy of chronic plaque psoriasis. Biologics 2009; 3: 159—168.Leonardi C.L., Kimball A.B., Papp K.A., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371 (9625): 1665—1674.Papp K.A., Langley R.G., Lebwohl M., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; May 17; 371(9625):1675-84.Leonardi C.L., Kimball A.B., Papp K.A. et al. PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; May 17; 371 (9625): 1665—74.Gordon K. et al. Sustained Efficacy of Ustekinumab for the Treatment of Moderate to Severe Psoriasis in Initial Responders Continuing with Maintenance Therapy Through Year 3. Poster presented at the Psoriasis 2010 congress, Paris, France, 1-4th of July 2010.Gordon K. et al. The ustekinumab ab safe experience in patients with moderate-to-severe psoriasis: Result From pooled analysis Of Phase 2 and Phase 3 clinical trial data. Poster Presented at the18th Europe an Association of DermatologyСура М.В., Авксентьева М.В., Омельяновский В.В. и др. Клинико-экономический анализ применения устекинумаба (Стелара) у пациентов с тяжелой степенью псориаза. Вестн. дерматол. и венрол. 2011; 3: 63—69.Menter A., Feldman S.R., Weinstein G.D. et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007 Jan; 56 (1): 31.